Prashant Kumar

Navigating medical device biocompatibility evaluations can often feel like solving a maze blindfolded, especially when trying to reconcile shifting global standards with FDA expectations. Fortunately, the FDA recently hosted the final installment of its comprehensive three-part town hall series, bringing together regulatory experts to demystify toxicological risk assessments (TRAs). Drawing from updated consensus standards like … Read more

For decades, bringing a rare disease therapy through the regulatory gauntlet has felt less like a science and more like navigating an obstacle course blindfolded. With roughly ninety-five percent of recognized rare conditions still lacking an approved treatment, the human and economic tolls have continued to mount unabated. Traditional clinical trial paradigms simply break down … Read more

The mandatory implementation of FDA’s electronic Individual Case Safety Report (ICSR) standards was announced this week requiring an overhaul of legacy safety reporting processes. With this announcement, FDA formally adopted ICH E2B(R3) framework for compliance. Sponsors must immediately align data architectures to satisfy stringent validation parameters and avoid costly workflow rejections.   The goal of ICH … Read more

For years, the scientific community has debated and critiqued a purported “replication crisis” that threatens to undermine public trust in medical research. Headlines frequently blare that dozens of published preclinical and clinical studies cannot be successfully reproduced under identical laboratory conditions. Yet treating reproducibility as a simple, binary pass-or-fail test fundamentally misrepresents the diverse, complex … Read more

Developing an innovative biologic for two major regulatory markets can sometimes feel like solving the same problem twice. FDA and EMA may ask similar questions, but that does not mean they will always give the same answers. That is where Parallel Scientific Advice (PSA) can make the development conversation much more coordinated. Instead of navigating … Read more

For medical device companies, FDA review time is more than a number on a performance chart, it can determine how quickly an innovation reaches patients. MDUFA V promised to make the regulatory process more efficient, predictable, and transparent. Now, an independent assessment by Booz Allen Hamilton provides a detailed look at what actually changed. The … Read more

Navigating the complex landscape of medical device regulation has always required immense patience, meticulous documentation, and strategic foresight. For years, medical device innovators have wrestled with customized submission formats that slow down the journey from breakthrough concept to patient care. Fortunately, the FDA is actively reshaping this journey with a streamlined, digitized approach to market … Read more

For decades, bringing a new drug to market meant one inevitable, heartbreaking reality: rows of laboratory animals sacrificed in the name of safety. Now, a sweeping regulatory shift by the FDA promises to usher in a modern era where computer models and organ chips take center stage. But before animal rights advocates pop the champagne, … Read more

Bringing a novel medical device from the whiteboard to the operating room is an exhilarating journey, but it frequently hits an abrupt wall at regulatory review. Developers often assume that running a standard battery of laboratory tests will automatically satisfy agency reviewers. In reality, the FDA does not evaluate safety in a vacuum; they evaluate … Read more

In the world of medical research, prespecified primary outcomes are supposed to be the immovable target that ensures scientific honesty. Yet, historical monitoring of thousands of clinical trials has long been bogged down by tedious manual curation. Enter the power of artificial intelligence, bringing unprecedented scale to the oversight of clinical evidence. A groundbreaking new … Read more